Important Safety Information

Warnings and Precautions: Gallbladder abnormalities may occur: Patients should be monitored periodically. Glucose Metabolism: Hypoglycemia or hyperglycemia may occur. Blood glucose levels should…

See More

Indication

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for long-term maintenance therapy in acromegalic patients who have had inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal).

Acromegaly

PANO

Novartis Oncology shares your commitment to helping patients receive the medicines prescribed. Patient Assistance Now Oncology (PANO) provides access to information and our wide range of resources available to your patients in over 160 languages.

Support for patients includes:

    • Insurance benefits verification, including information on denials/appeals
    • Information about financial assistance that may be available
    • Patient Support Counselors who are able to provide information in over 160 languages
    • One dedicated case manager/single point of contact per case

To learn more, call 1-800-282-7630.

Co-Pay Assistance

At Novartis Oncology, we’ve made it easier than ever for patients to access financial support on their prescription costs for almost all Novartis Oncology products.

With the Novartis Oncology Universal Co-Pay Program, eligible, commercially insured patients may pay no more than $25 per month, and Novartis will pay the remaining co-pay, up to $15,000 per calendar year.

Limitations apply. Offer is not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice.

Encourage your patients to find out if they are eligible to enroll in the Universal Co-Pay Program by visiting www.CoPay.NovartisOncology.com or calling 1-877-577-7756.

 

Save on your out-of-pocket costs

Mobile Administration Program:

When caring for patients who are receiving Sandostatin® LAR Depot (octreotide acetate for injectable suspension) therapy, you know how important it is to administer injections exactly as prescribed. But you also know that it's not always easy for some of your patients to get to the office to receive their injections by a trained health care provider.

The Sandostatin Mobile Administration Program is not intended to replace the care provided by you and your office, but to help eligible patients receive their injections on schedule at home or at a location convenient to them, by a trained health care professional. Through this program, you will receive regular patient reports, to keep you up to date on your patients' receipt of Sandostatin LAR Depot injections.

Which patients are eligible?

The MAP is an additional benefit for all appropriate and eligible patients with acromegaly for whom Sandostatin LAR Depot has been prescribed.

  • Patients must be recommended by their physician
  • Residents of all states except Massachusetts, Michigan, Minnesota, and Rhode Island can participate
  • The program is available to patients covered by most commercial plans (HMO, PPO, etc)
  • Patients with government-provided medical insurance (eg, Medicare Part B and D, or Medicaid) are not eligible

Your office can confirm patient eligibility easily by calling 1-877-503-3377 and speaking with a representative. You can also print the enrollment form by clicking here.

Advantages of the MAP

Because the program provides specially trained registered nurses, you can feel confident about the following:

  • No guesswork. You know that your patient will receive the right dose, at the right time, using the right technique
  • Feedback from registered nurses. The nurse will submit a detailed report to you after each visit. You will know when the patient receives his/her treatment at the prescribed dose
  • Your patients can receive injections when it is convenient for their schedule. Nurses are available outside traditional office hours, including weekends and evenings, even when patients are traveling within the continental United States
  • Time saved for your patient. Your patient won't need to make long trips to the treatment center
  • Nurse handles all needle disposals. The program nurse handles disposal of all equipment
    • The MAP program is not intended to replace the care provided by a patient's health care team

How MAP works

  • As the prescribing physician, you evaluate your patients on a case-by-case basis and decide who is appropriate for the program
  • Your office submits the patient's information to the company that administers the program, in one of two ways:
    • By calling 1-877-503-3377 or
    • By completing and sending in the enrollment form
  • Patient eligibility is verified according to your patient's insurance plan
  • Your patient receives a call to schedule the next injection at the patient's schedule. (Patients must receive their first dose of Sandostatin LAR Depot in your office)
  • A specially trained treatment nurse visits your patient's home and:
    • Administers the injection
    • Schedules the next appointment and follows up with a reminder
    • Sends a report to you, the prescribing physician, to update you on the patient’s status

Important things to note about the MAP

  • The program does not replace your care or the authority of the prescribing physician. It simply provides your patients with the convenience of home injections. Patients still keep their regular, scheduled physician checkups
  • Patients must receive their first dose of Sandostatin LAR Depot in your office
  • Nurses who take part in this program are specially trained to mix and administer Sandostatin LAR Depot

SANDOSTATIN® LAR Depot

INDICATION

Sandostatin LAR Depot (octreotide acetate for injectable suspension) is indicated for patients in whom initial treatment with immediate release Sandostatin (octreotide acetate) Injection has been shown to be effective and tolerated for long-term maintenance therapy in acromegalic patients who have had inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions:

  • Gallbladder abnormalities may occur: Patients should be monitored periodically.
  • Glucose Metabolism: Hypoglycemia or hyperglycemia may occur. Blood glucose levels should be monitored when Sandostatin LAR Depot treatment is initiated or when the dose is altered. Antidiabetic treatment should be adjusted accordingly.
  • Thyroid Function: Hypothyroidism may occur. Baseline and periodic assessment of thyroid function (TSH, total and/or free T4) is recommended.
  • Cardiac Function: Bradycardia, arrhythmia, conduction abnormalities, and other EKG changes may occur. The relationship of these events to octreotide acetate is not established because many of these patients have underlying cardiac disease. Use with caution in at-risk patients.
  • Nutrition: Octreotide may alter absorption of dietary fats. Monitoring of vitamin B12 levels is recommended during therapy with Sandostatin LAR Depot. Patients on total parenteral nutrition (TPN) and octreotide should have periodic monitoring of zinc levels.

Drug Interactions:

The following drugs require monitoring and possible dose adjustment when used with Sandostatin LAR Depot: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Drugs mainly metabolized by CYP3A4 and which have a low therapeutic index should be used with caution.

Adverse Reactions:

The most common adverse reactions occurring in patients receiving Sandostatin LAR Depot were biliary abnormalities (52%), diarrhea (36–48%), cholelithiasis (13–38%), abdominal pain or discomfort (11–29%), flatulence (26%), influenza-like symptoms (20%), constipation (19%), headache (15%), anemia (15%), hyperglycemia (15%), injection site pain (2–14%), hypertension (13%), dizziness (12%), fatigue (11%), nausea (10%), vomiting (7%), hypothyroidism (2%), hypoglycemia (2%), and goiter (2%).

Please see full Prescribing Information.